Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation

Bone Marrow Transplantation volume 45, pages 798–800 (2010)Cite this article

Post-essential thrombocythemia myelofibrosis (post-ET MF) may occur as a late event during the course of ET.1 Criteria for diagnosis of post-ET MF have been recently established by the International Working Group on Myelofibrosis Research and Treatment.2 Once ET evolves into post-ET MF, survival is worsened, and in a few instances hemopoietic allo-SCT may be considered as a treatment option.3, 4 Patients with myelofibrosis may carry the JAK2 (V617F) mutation5 or, more rarely, mutations within the MPL gene.6 This allows one to study minimal residual disease after allo-SCT by monitoring these activating molecular mutations in positive patients.7, 8

Herein, we report the clinical course and minimal residual disease in a man with post-ET MF carrying the MPL mutation, who received allo-SCT. The patient gave his written informed consent for DNA studies. At the age of 49 years, the patient developed post-ET MF after 108 months of ET. Diagnosis of disease evolution was based on the International Working Group on Myelofibrosis Research and Treatment criteria.2 When he was referred to our Division of Hematology, he had transfusion-dependent anemia (Hb 7.1 g per 100 ml), leukopenia (WBC 3.4 × 109/l) and splenomegaly. Circulating CD34+ cells were at the upper normal range (49 × 106/l) and the lactate dehydrogenase level was elevated (1085 mU/ml). His BM biopsy showed hypercellularity (90%), megakaryocytic hyperplasia with atypia, grade 2 myelofibrosis according to the European Classification and a 3% CD34+ blast cell count. The patient had a normal diploid karyotype. High-resolution melting and sequencing analyses on circulating granulocytes showed an MPL W515A mutation.9 After failure of conventional treatments, he received a matched unrelated-donor allo-SCT. A fully myeloablative conditioning, including TBI (1200 rad in six doses) and CY (60 mg/kg/day for 2 days), was given. A total of 8.9 × 106/kg peripheral CD34+ cells were infused. Engraftment was achieved on day +16 after transplantation. During the post-transplant period, CMV reactivation occurred and required treatment with ganciclovir. At day +100, a CR was documented on the basis of the International Working Group criteria:10 resolution of splenomegaly, normal peripheral blood counts and leukocyte differential, and normal BM histology without fibrosis. Circulating CD34+ cells were within the normal range (3.1 × 106/l).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270–276.

    Article  CAS  PubMed  Google Scholar 

  2. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437–438.

    Article  CAS  PubMed  Google Scholar 

  3. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918.

    Article  CAS  PubMed  Google Scholar 

  4. Gupta V, Kroger N, Aschan J, Xu W, Leber B, Dalley C et al. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant 2009 (e-pub ahead of print 23 February 2009).

  5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  PubMed  Google Scholar 

  6. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316–1321.

    Article  PubMed  Google Scholar 

  8. Benjamini O, Koren-Michowitz M, Amariglio N, Kroger N, Nagler A, Shimoni A . Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 2008; 22: 1961–1963.

    Article  CAS  PubMed  Google Scholar 

  9. Pietra D, Rumi E, Brisci A, Passamonti F, Boggi S, Cremonesi L et al. Loss of heterozygosity of chromosome 1p34 and high mutant allele burden in patients with post-essential thrombocythemia myelofibrosis carrying somatic mutations of Mpl. Blood 2008; 112: 176a.

    Google Scholar 

  10. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497–1503.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Fondazione Cariplo, Milan, Fondazione Ferrata Storti, Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, and from the Ministry of University and Research, Rome, Italy

Author information

Authors and Affiliations

  1. Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

    E Rumi, F Passamonti, L Arcaini, P Bernasconi, C Elena, D Pietra, M Cazzola & M Lazzarino

  2. Genomic Unit for the Diagnosis of Human Pathologies, Center for Genomics, Bioinformatics and Biostatistics, San Raffaele Scientific Institute, Milano, Italy

    A Brisci

  3. Department of Surgical Pathology,

    E Arbustini

  4. , Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

    E Arbustini

Authors
  1. E Rumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Passamonti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Arcaini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Bernasconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Elena
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Pietra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Brisci
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Arbustini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Cazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Lazzarino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Rumi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rumi, E., Passamonti, F., Arcaini, L. et al. Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplant 45, 798–800 (2010). https://doi.org/10.1038/bmt.2009.231

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.231

This article is cited by

Search

Advanced search

Quick links